Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Jazz Pharmaceuticals (JAZZ) PT Lowered to $190 at Stifel Following 4Q
March 1, 2017 9:00 AM ESTStifel lowered its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $190.00 (from $200.00) while maintaining a Buy rating.
Analyst Annabel Samimy commented, "JAZZ reported 4Q16 revenue of $396.6mn (Cons. $398.3mn), representing +16.4% y/y. Top-line was driven by Xyrem with sales of $291.2mn (Cons.... More
